argenx
Works in Dermatology · Genetic & rare · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
argenx is a clinical trial sponsor. It has 43 active clinical trials with 5,873 planned participants, across 13 therapeutic areas. Since 2021 it has completed 30 trials and stopped 7 early.
Trial track record · since 2021
Pipeline · 43 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about argenx
argenx is lead sponsor of 43 active clinical trials on ClinicalTrials.gov, with 5,873 planned participants, in Dermatology, Genetic & rare, Hematology, Immunology and other areas. Since 2021 it has completed 30 trials and stopped 7 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with argenx; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with argenx. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.